Transportation of Nanoscale Cargoes by Myosin Propelled Actin Filaments

Malin Persson1, Maria Gullberg1*, Conny Tolf1, A. Michael Lindberg1, Alf Månsson1*, Armagan Kocer2*

1 School of Natural Sciences, Linnaeus University, Kalmar, Sweden, 2 Biochemistry Department, University of Groningen, Groningen, The Netherlands

Abstract

Myosin II propelled actin filaments move ten times faster than kinesin driven microtubules and are thus attractive candidates as cargo-transporting shuttles in motor driven lab-on-a-chip devices. In addition, actomyosin-based transportation of nanoparticles is useful in various fundamental studies. However, it is poorly understood how actomyosin function is affected by different number of nanoscale cargoes, by cargo size, and by the mode of cargo-attachment to the actin filament. This is studied here using biotin/fluorophores, streptavidin, streptavidin-coated quantum dots, and liposomes as model cargoes attached to monomers along the actin filaments (“side-attached”) or to the trailing filament end via the plus end capping protein CapZ. Long-distance transportation (>100 µm) could be seen for all cargoes independently of attachment mode but the fraction of motile filaments decreased with increasing number of side-attached cargoes, a reduction that occurred within a range of 10–50 streptavidin molecules, 1–10 quantum dots or with just 1 liposome. However, as observed by monitoring these motile filaments with the attached cargo, the velocity was little affected. This also applied for end-attached cargoes where the attachment was mediated by CapZ. The results with side-attached cargos argue against certain models for chemomechanical energy transduction in actomyosin and give important insights of relevance for effective exploitation of actomyosin-based cargo-transportation in molecular diagnostics and other nanotechnological applications. The attachment of quantum dots via CapZ, without appreciable modulation of actomyosin function, is useful in fundamental studies as exemplified here by tracking with nanometer accuracy.

Introduction

Intracellular transport of nanoscale cargoes (lipid vesicles, mitochondria etc.) is executed by molecular motors [1,2] such as kinesins and dyneins, walking along tracks of microtubules and myosins walking along actin filaments. This has inspired development of molecular motor driven lab-on-a-chip devices [3,4,5,6,7] with cargo pick-up and transportation [8,9,10,11,12,13,14,15,16,17]. Possible applications include periodic chemistry [18,19], assembly of molecular components [20,21,22], sorting, positioning and/or concentration [20,23,24,25,26,27] of molecules. Even proof-of-principle diagnostics devices [20,29,30,31,32] have been described, with significant future potential [3,7]. In the mentioned applications, cargo-transportation usually relies on surface immobilization of the motors with microtubules and actin filaments as “shuttles” with attached cargoes of nanometer (e.g. oligonucleotides, proteins or nanoparticles) to micrometer size (e.g. polystyrene beads, bacteria or large liposomes) [10,12,13,14,21,22,29,33,34,35,36,37,38,39,40,41]. In a vast majority of these studies the microtubule-kinesin motor system has been employed, partly due to the belief that effective cargo-transportation is considerably more challenging with actomyosin [7,11,42,43], e.g. related to possible rotation of the filaments around their long axis [44,45]. Such rotation may be deleterious if bulky cargoes are attached to the actin monomers along the filament length (“side-attached”). Accordingly, in several recent studies the cargoes have been attached either to bundled actin filaments [15,37] (with increased complexity) or to the trailing end (“end-attached”) of the filament via the capping protein gelsolin [10,33,40]. Even though the latter approach would alleviate rotation-induced clashes with a dense motor layer, the small capacity for cargo loading would be a limitation in nanotechnological applications. On the other hand, the attachment to the trailing end may be useful for fundamental studies, e.g. labelling of the filament plus end [46], tracking with nanometer accuracy [47,48] and application of loads to

Citation: Persson M, Gullberg M, Tolf C, Lindberg AM, Månsson A, et al. (2013) Transportation of Nanoscale Cargoes by Myosin Propelled Actin Filaments. PLoS ONE 8(2): e55931. doi:10.1371/journal.pone.0055931

Editor: Laurent Kreplak, Dalhousie University, Canada

Received October 18, 2012; Accepted January 3, 2013; Published February 21, 2013

Copyright: © 2013 Persson et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was funded by the Carl Trygger Foundation, the European Union Seventh Framework Programme (FP7/2007–2011) under grant agreement number 228971 (MONAD), the Swedish Research Council (Project #621-2007-6137 and #621-210-5146), the Faculty of Natural Sciences and Engineering at Linnaeus University and the Netherlands Organisation for Scientific Research (NWO/VIDI Grant 700.57.427 to AK). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have read the journal’s policy and have the following conflicts: Alf Månsson is a co-founder, co-owner and CEO of the start-up company ActoSense Biotech AB (Kalmar, Sweden) aiming to develop diagnostic devices based on the aggregation of cytoskeletal elements, particularly actin filaments, in solution. Moreover, A. Månsson holds two Swedish patents in this field and application for one of these patents (about aggregation of actin filaments by analyte molecules) has also been filed in the US and Europe. A. Swedish patent 1: Månsson A, Tägerud S, Sundberg M, Rosengren JP, Montelius L, Omling P, Burk R, Nichols JA and Balaz M. (2007) Arrangement for an miniaturised separation of biomarkers and other substances using aggregation of actin filaments. Swedish Patent SE 528 790 B. Swedish patent 2: Månsson, A and Tägerud, S. (2008). Känslig detektering av gifter, patogener och sjukdomsmarker genom aggregation av cytoskeletala filament. Swedish Patent SE 531 135. B1. European patent application based on Sw. patent 2: Detection conjugate. Application number: EP2007852077 B2. US patent application based on Sw. patent 2: Detection conjugate. Application number: 12/517,148; Publication number: US 2010/0248212 A1. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.

* E-mail: alf.mansson@lnu.se (AM); a.kocer@rug.nl (AK)

# Current address: National Veterinary Institute, Technical University of Denmark, Lindholm, Kalvehave, Denmark
the actin filaments via magnetic particles [10]. However, in this case it is important to ensure that the capping protein itself does not affect the actomyosin function, a possibility with gelsolin [49] since actin filament structure is modified by interactions of gelsolin with the actin monomer at the filament end [50,51,52,53]. In view of the ten-fold higher speed of actomyosin driven transportation compared to microtubule-kinesin driven transportation and the perceived [7] difficulties in using actin filaments as shuttles, it is of interest to define the maximum capacity of cargo transportation with side-attached cargoes of different size for effective use in various nanodevices. Based on limited evidence in the literature [11,32,37], we hypothesize that the capacity is high for protein-sized cargoes, but quite small for slightly larger cargoes (e.g. quantum dots), due to rotation of the filament around its long axis during sliding. We also hypothesize that any steric clashes due to rotation would be eliminated if the nanoparticles were attached to the trailing end of actin filaments via a suitable capping protein. Particularly, we postulate that CapZ, not previously tested for this purpose, would be suitable. Thus, unlike the capping protein gelsolin, CapZ does not sever actin filaments suggesting that structural changes in the filaments are more limited.

In order to address the above hypotheses, we here study actomyosin-based transportation of side-attached and end-attached model cargoes, including streptavidin, quantum dots and liposomes, of sizes comparable to diagnostically relevant antibodies, viruses and microvesicles, respectively (Fig. S1). Furthermore, we show, for the first time, transportation of cargoes attached to the trailing end of actin filament via the plus end actin capping protein CapZ [54,55,56]. The results with side-attached cargoes show that >1000 covalently immobilized biotins, >50 streptavidin molecules, >4 quantum dots and liposomes may be transported at similar velocity as in the absence of cargo. However, the fraction of motile filaments was reduced with increased degree of cargo loading. Whereas only limited effect was seen for up to 50 streptavidin molecules, quite severe effects were observed for just a few quantum dots or single liposomes. The results with end-attached cargoes suggest that CapZ does not cause noticeable effect on motility. The results are discussed in relation to future development of actomyosin-powered nanodevices and the use of nanoparticle-attachment in fundamental studies. Key results that shed new light on important mechanisms of actomyosin based motion generation are also discussed.

Materials and Methods

Ethics Statement

All experiments using animal material were approved by the Regional Ethical Committee for Animal experiments in Linköping, Sweden (reference numbers: 52–05, 58–08 and 96–11) and performed in accordance with national and EU legislations.

Abbreviations

A list of abbreviations (Abbreviations S1) is given in the Supporting Information.

Solutions and Chemicals

Actin monomers (G-actin) were dissolved in G-buffer: 2 mM tris-HCl pH 7.6, 0.2 mM adenosine-5’-triphosphate (ATP), 0.2 mM CaCl₂, 0.2 mM Dithiothreitol (DTT) and 0.2 mM Na₂S. Heavy meromyosin (HMM) and other proteins were diluted in a buffer A: 10 mM 3-morpholinopropan-1-sulfonic acid (pH 7.4), 1 mM MgCl₂, 0.1 mM ethylene glycol tetraacetic acid, 1–10 mM DTT and appropriate amounts of KCl to produce ionic strengths in the range 40–130 mM. All chemicals were of analytical grade and, if not otherwise stated, purchased from Merck (Darmstadt, Germany), Sigma-Aldrich (St. Louis, MO, USA) or Fluka and Riedel-de Haen (Seelze, Germany). Alexa Fluoro® 488 phalloidin (APh), rhodamine phalloidin (RhPh) and Qdot® 605 Streptavidin conjugate (quantum dot) were all purchased from Invitrogen - Molecular Probes (Eugene, OR, USA) while tetramethylrhodamine-isothiocyanate (TRITC)-streptavidin was purchased from Pierce (Rockford, IL, USA).

Protein Preparations

Actin and myosin II were isolated from rabbit back muscle and rabbit fast leg muscle [57]. Myosin was digested by α-chymotrypsin to prepare HMM [58], whereas actin was purified essentially as in [59] with special care taken to remove tropomyosin, tropolins and other soluble proteins. The G-actin was stored on ice and used within a week. Alternatively, G-actin or actin filaments (F-actin) were frozen in liquid nitrogen and stored at −80°C until use (cf. [60]).

CapZ was expressed in Escherichia coli (E. coli) and purified as described previously [54]. Briefly, the expression was induced with 0.1 mM isopropyl β-D-thiogalactopyranoside for 3 h before lysis of cells and purification on a HiTrapTM HP column (GE Healthcare Bio-Science AB, Uppsala, Sweden) according to manufacturers protocol. The purity of the actin and CapZ preparations are illustrated by the sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) in Fig. S2.

Protein Biotinylation and Covalent Rhodamine Labelling

Actin and CapZ were biotinylated with N-Hydroxysulfo succinimide (NHS) ester coupling chemistry using an EZ-Link Sulfo-NHS-LC-Biotinylation kit (Pierce) according to manufacturers protocol (see also [61]). Alternatively, CapZ was labelled with rhodamine using a NHS-Rhodamine antibody labelling kit (Pierce) according to manufacturer’s protocol resulting in 1–2 rhodamines per CapZ molecule. The extent of biotinylation according to 4’-hydroxylazobenzene-2-carboxylic acid assay was 0.8–1 biotins per actin monomer (unless otherwise stated) and 4–6 biotins per CapZ molecule. In the experiments using fluorescent TRITC-streptavidin there were 4 biotins per actin monomer and 2 TRITC molecules, on average, per streptavidin.

Biotinylated Liposome Preparation

All lipids were purchased from Avanti Polar Lipids Inc. Alabaster, Alabama. Liposomes were prepared from 1,2-Diphytanoyl-sn-Glycero-3-Phosphocholine, 1-Palmitoyl-2-Oleoyl-sn-Glycero-3-[Phospho-rac-[1-glycerol]], cholesterol and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[biotinyl(polyethylene glycol)-2000] (ammonium salt) with a ratio 70:25:5:1 wt. % as explained before [62]. Briefly, lipids from chlororom stocks were mixed at the desired weight ratio and a thin lipid film was obtained by evaporating the chloroform in a rotary evaporator. The lipid film was rehydrated at 50°C for 45 min by adding 1 ml buffer (10 mM Tris, pH 7.5). After 5 freeze and thaw cycles in liquid nitrogen and 50°C water-bath, respectively, the liposomes were stored at −80°C for further use. Before experiments, pre-warmed liposomes (10 mg/ml) were extruded 11 times through a 400 nm pore size polycarbonate filter (Avestin) and the resulting large unilamellar vesicles were titrated at 50°C with Anapoe®-X-100 (Triton X-100) until saturation. The detergent-stabilized liposomes were mixed with 1 volume of 200 mM calcium (Na-salt) (Sigma). Detergent removal was achieved by incubating the mixture with 200 mg wet weight of Bio-Beads SM-2 adsorbents (Bio-Rad Laboratories, Hercules, CA, USA) at 4°C. This
procedure yields biotinylated unilamellar liposomes (average diameter of 100 nm) with 100 mM fluorescent calcine inside [63].

**In vitro Motility Assay – General Aspects**

All dilutions of proteins and washing steps were performed using buffer A with ionic strength of 60–80 mM unless otherwise stated. In **in vitro** motility assays were performed according to standard methods [42,58,61], where 50–120 μg/ml rabbit HMM was first adsorbed to cover glasses derivatized with trimethylchlorosilane (TMCS, Sigma; [43,64]). Subsequently, the **in vitro** motility assay flow cell was incubated with 1 mg/ml biotin-free bovine serum albumin fraction V (BSA; Sigma-Aldrich) for 30 s – 1 min. In some experiments, ATP insensitive “rigor heads” of HMM were either removed by affinity precipitation using ultracentrifugation in the presence of F-actin and ATP [65] or by incubating 1 μM non-fluorescent “blocking actin” directly in the flow cell before introducing fluorescent/biotinylated F-actin (2–10 nM; monomer concentration). F-actin was labelled with RhPh or APh as in [58]. All assay solutions contained 1 mM MgATP (unless otherwise stated), had pH 7.4 and were supplemented with an oxygen concentration (40, 60, 80, 90, 130 mM (AMc 130) as adjusted with KCl. In the AMc90 and AMc130 assay solutions, 0.5–0.6% methylcellulose (M0262, Sigma-Aldrich; 2% aqueous solution) was added to cover glasses derivatized with trimethylchlorosilane (TMCS, Sigma-Aldrich; [43,64]). Images were acquired using an electron multiplying charge coupled device (EMCCD) camera (C9100-12, Hamamatsu) equipped with a TIRF objective (60x, NA 1.49, Nikon) and a 532 nm diode laser for illumination. Actin filaments that were labelled with RhPh, TRITC-streptavidin or quantum dot were visualized using a TIRF filter-set (Ex. 540/25, DM 565, BA 605/55). APh-labelled actin filaments or calcine loaded liposomes were visualised by a fluorescein isothiocyanate (FITC) filter-set (Ex. 465/495, DM 505, BA 515–555). Images were acquired using an electron multiplying charge coupled device (EMCCD) camera (C9100-12, Hamamatsu Corporation, Hamamatsu, Japan). The sequence of images was captured at 5 s−1. The sliding velocities were estimated from these image sequences using a manual version of a previously described tracking program [66,67]. In this software, an algorithm searches for the 10 frames in a row, where the coefficient of variation (CV) of the frame-to-frame velocity is lowest (cf. Fig. S3). If not otherwise stated, the velocity data below refer to the mean value for several filaments of such 10-frame averages with CV <0.5. Another measure of velocity, the average velocity (Fig. S3A), was obtained by dividing the distance moved with the time (generally in the range of 5–20 s) over which the movement took place. Here, all moving (but not entirely stationary) filaments were included in the analysis whether they moved smoothly or not. When different conditions (e.g. different number of quantum dots per filament) were compared, similar time (number of image frames) was used for all conditions. For velocity-length plots, actin filament lengths were obtained from filament intensity as described previously [42].

**In vitro Motility Assay with Nanoscale Cargoes Attached along Actin Filaments**

TRITC-streptavidin (1–100 nM) or streptavidin coated quantum dots (2–10 nM) were incubated for 1 min in flow cells with biotinylated actin filaments attached to HMM. The flow cell was washed before the motility was initiated by addition of the different assay solutions (A40, A80, or AMc130). For experiments in which free biotin in solution was used to block the unoccupied biotin-binding sites of streptavidin, the flow cell was washed with 20 nM–40 μM biotin before the motility was initiated by addition of AMc130. This gave at least 8 times higher concentration of free biotin than the incubated streptavidin concentration.

For liposome attachment, RhPh labelled and biotinylated F-actin was first immobilised on HMM before incubation with non-fluorescent streptavidin (24 nM) for 1 min. Subsequently, two rinsing steps were imposed before calcine filled liposomes were added to the flow cell. Finally, the flow cell was further washed two times before the motility was initiated by infusing AMc130 solution.

**In vitro Motility Assay with Nanoscale Cargoes Attached to the Trailling End of Actin Filaments**

Actin filaments capped with CapZ were tracked by fitting a two-dimensional Gaussian function [47] to the diffraction limited intensity distribution of the quantum dot. The image frames in these experiments were captured using an EMCCD chip (C9100-12, Hamamatsu; see above) with a pixel size corresponding to 165×165 nm2 on the flow cell using a 100×objective (NA 1.4). The frame rate was 5 frames/s. Repeated measurements using stationary quantum dots suggested a tracking accuracy of ±5 nm (standard deviation).
Data Analysis
Data are expressed as mean ± standard error of the mean (SEM) or as mean ± 95% confidence interval (CI) as indicated. Linear and non-linear regression and other statistical analyses were performed using GraphPad Prism software (version 5.01, GraphPad Software, San Diego, CA, USA).

Results
Negligible Effects on Motility of more than Thousand Small Molecules and Tens of Streptavidin Molecules Per μm of an Actin Filament

The approximately 360 actin monomers per μm of an actin filament [68,69], each with reactive lysines and cysteines, serve as regularly spaced and naturally occurring sites for covalent modification [32], e.g. biotinylation. Thus, in order to attach streptavidin-labelled cargoes to F-actin, the filaments were first covalently biotinylated with 1–4 biotins per actin monomer (~360–1500 per μm of the filament). In these and other experiments in the present study, the biotins were attached to lysines on actin and both biotinylation and subsequently streptavidin binding would be most likely for the most accessible lysines in the order: (i) Lys-113, (ii) Lys 215 and (iii) Lys-50, Lys-191, Lys-204, Lys-291, Lys-315, Lys-326 and Lys-359 (Analysis using Swiss-Pdb Viewer 4.0,44 http://www.expasy.org/spdbv/ of Protein data bank entry 1M8Q). This biotinylation (Fig. 1, Table 1) had, in itself, negligible effects on the HMM induced actin sliding velocity and on the fraction of motile filaments whether pre-incubation with blocking actin (to block rigor-like heads) was employed or not. Moreover (Table 1), actin filaments exhibited similar sliding velocities (cf. [60]) and fractions of motile filaments whether they were labelled with APb or RlPh. To study the interaction between biotinylated actin filaments and fluorescent streptavidin (~5 nm in diameter), biotinylated actin filaments (4 biotins per actin) were first immobilized to HMM on the surface before incubation with 1–100 nM TRITC-streptavidin. This caused appreciable concentration dependent (Fig. 1A, B) streptavidin labelling (5–60 streptavidin molecules/μm). In addition, there was non-specific binding of TRITC-streptavidin to the HMM coated surface (Fig. 1A–B) even if BSA had been used to block non-specific binding. In the absence of free biotin in the solution (e.g. Fig. 1A; Movie S1) there was increased tendency for blocking of the motility by inter- and intrafilament cross-linking via biotin-streptavidin-biotin links. This was particularly seen at low streptavidin loading of the filaments with a large number of free biotin molecules accessible on actin. An observation worth noting in this connection, is the self-assembly of actin filament spools (insets Fig. 1A, Movie S1; see previous microtubule results [70]) stabilized by intrafilament biotin-streptavidin mediated cross-links particularly seen with low streptavidin loading on actin. Addition of biotin to the streptavidin labelled filaments under these conditions reduced the actin filament cross-linking via streptavidin-biotin links (Fig. 1A, C). A similar effect of biotin was not observed at high streptavidin loading (Fig. 1B, C; Movie S2).

The sliding velocity during periods of smooth sliding (CV of frame-to-frame velocity <0.5) was only negligibly affected by binding of 1–60 streptavidins/μm (Fig. 1D). In contrast, the average velocity (including periods with temporarily halted motility) was reduced with increased number of streptavidin molecules in one of the two separate experiments (Fig. 1E). This is consistent with the increased fraction of stationary filaments, which, however, was observed in both experiments (Fig. 1C).

Side-attached Quantum Dots have Minimal Effects on Sliding Velocity
Next, we studied the effect of larger cargos by attachment of streptavidin coated semiconductor quantum dots to the filaments. The quantum dots had 5–10 streptavidin molecules immobilized on the surface and exhibited smaller and large axes diameters of 15 and 20 nm, respectively (manufacturers specifications). The approximate diameters in the absence of streptavidin were 5 and 12 nm, respectively. In a first set of experiments, biotinylated actin filaments were incubated for ~2 min with streptavidin coated quantum dots (2 nM) while immobilised to HMM in the in vitro motility assay flow cell. This led to binding of mostly one, but occasionally two quantum dots to between 3 and 15% of the filaments in 6 different experiments (mean 7.5±1.7%; Movie S3). A similar total number of non-specifically bound quantum dots were observed on the flow cell surface outside the biotinylated filaments. The sliding velocity was not appreciably affected by the quantum dot attachment whether pre-incubation with blocking actin (non-fluorescent actin filaments to block dead heads) was employed or not (Table 1, last row). Moreover, in great contrast with previous studies using quantum dot-attachment to actin filaments via biotin-phalloidin, we observed events with long-distance transportation (>100 μm; Fig. S3) at ionic strengths up to 80 mM in the absence of viscosity enhancing methylcellulose.

The effects of quantum dot loading on HMM induced actin filament sliding at varying ionic strengths are illustrated in Fig. 2 for experiments distinct from those in Table 1 (and at higher temperatures than these). In accordance with data in Table 1, the fraction of motile filaments (Fig. 2A) tended to be reduced, whereas the velocity (Fig. 2B) was minimally affected by quantum dot attachment at all ionic strengths tested.

In another set of experiments, biotinylated actin filaments were incubated with quantum dots under conditions resulting in 1 to >5 quantum dots per filament and also to the formation of cross-linked filament aggregates (Fig. 3A, Movie S4). It can be seen in Fig. 3B that the fraction of motile filaments decreased with an increased number of quantum dots in the range 1–4, whereas there was negligible effect on sliding velocity (Fig. 3C). This lack of effect on velocity remained during up to 10 min observation period (Fig. S4A).

Motility (sometimes good) was also observed for larger number of quantum dots, but in these instances (cf. Fig. 3A, Movie S4) it was usually difficult to count the exact number of quantum dots or clarify to what degree the filaments were aggregated via quantum dot-streptavidin-biotin bonds. Therefore, no quantitative estimates of motility quality were obtained for >4 quantum dots per filament. Neither did we attempt detailed studies of the concentration dependence of the degree of quantum dot binding to the actin filaments. The short incubation times and rather low quantum dot concentrations used here were chosen to limit the degree of non-specific binding outside the filaments. A limitation on actin binding in this case was not saturation of binding sites but rather the slow diffusion of the comparatively large quantum dots to the binding sites on actin [71]. In some random instances, two parts of a filament (e.g. leading and trailing; Fig. S5) were loaded with several quantum dots, whereas the remaining part(s) of the filament was unlabelled. Filaments of this type moved over large distances without appreciable tendencies for stops and pauses. For instance, the filament in Fig. S5 that initially had 4–5 quantum dots at each end (2 in front end detached after about 10 μm of sliding), moved for >>100 μm at an average velocity of 1.72 μm/s compared to 1.73±0.096 μm/s (n = 18 filaments) in the absence of quantum dots in the same flow cell.
An additional observation of interest was that one filament with two quantum dots executed nearly continuous counterclockwise rotation for 164 s, apparently with one of the actin-attached quantum dots as an axis. Altogether, 30 full rotations in the same direction were observed. Similar behaviour is observed for one filament in Movie S4 (in the lower right, second half of the movie).

Liposomes can be Transported at High Sliding Velocity
Streptavidin-mediated attachment of biotinylated liposomes (diameter $\geq 50$ nm) along actin filaments had greater effect on HMM induced sliding than quantum dot attachment. In this case, a reduced fraction of motile filaments (Fig. 4A) with increased number of attached liposomes was associated with slightly reduced velocity (Fig. 4B; Movie S5). Large liposomes ($>100$ nm in diameter) occasionally caused filament detachment from the

Figure 1. Effect of different degrees of streptavidin labelling on HMM induced actin filament motility. **A.** Biotinylated and APH labelled F-actin (5 nM), immobilized to HMM on a surface, then incubated with 1 nM TRITC-streptavidin for 1 min followed by rinsing and incubation by AMc130 assay solution. Observation using TRITC filter set. Arrow indicates motile TRITC-streptavidin labelled filament. Other filament-like objects represent cross-linked and non-motile filaments. Inset: nanospool of actin filament formed by intra-filament biotin-streptavidin cross-linking. Left image, TRITC-filter set to observe TRITC-streptavidin. Right image, FITC-filter set to observe Alexa-488-labelling of the same filament. **B.** Same conditions as in A except for incubation with 20 nM TRITC-streptavidin and 40 \( \mu \)M biotin in solution. Arrows indicate motile filaments. Note, brighter background than in A, presumably due to non-specific binding of TRITC-streptavidin. **C.** Fraction of motile filaments vs. average number of streptavidin molecules per \( \mu \)m filament length. Vertical error bars: SEM. Horizontal error bars: standard deviation. **D.** Velocity for filaments with different number of streptavidin molecules measured during the periods of smoothest sliding (CV $<0.5$). **E.** Average velocity during 6–16 s plotted against number of streptavidin molecules per filament length. Black and grey symbols: two different experimental dates with different HMM, actin and streptavidin batches. Red symbols: covalently biotinylated F-actin with addition of 0–20 nM TRITC-streptavidin followed by 20 nM to 40 \( \mu \)M biotin, prior to motility assay. Same experimental date as black. Straight full lines obtained by linear regression as well as dashed lines representing 95% confidence intervals.

doi:10.1371/journal.pone.0055931.g001
surface. The average velocity of filaments with one attached liposome did not change appreciably over a 10 min period as tested in one experiment (Fig. S4B). Most actin filaments in the experiments with liposomes presumably had several more streptavidin molecules attached than those required to link the liposome to the filament, possibly contributing to lower fraction of motile filaments (see above).

In some experiments, we observed large liposomes (as suggested by high fluorescence intensity; Movie S6) that appeared to roll on the surface with a velocity similar to that for filaments without liposomes. The actin filaments in such experiments, observed by switching to a TRITC filter-set, appeared as ellipsoids or spheres with greater width than other filaments in the image (Movie S6). A possible interpretation is that one actin filament was bent around the liposome in a way that the bend and two ends of the filament are not fully resolved in the microscope. Indeed, the actual formation of such a bend was directly observed in one case. Alternatively, in other cases two or more actin filaments may have attached on the liposome. This is similar to a strategy systematically exploited for liposome transportation in a recent study [41].

CapZ is a Potential Alternative to Gelsolin for Attaching Cargos to the Plus End of Actin Filaments

Here, we describe the first in vitro motility assay study using actin filaments with CapZ attached to the actin filament plus end (according to search on PubMed September 22, 2012). Polylhistidine tagged CapZ was expressed in E. coli [54] and purified (Fig. S2), as described previously [34,55]. For our experiments, CapZ was either biotinylated or labelled with rhodamine, using NHS-ester based conjugation chemistry. Both the α- and θ subunits of the CapZ heterodimer were labelled by these procedures as suggested by fluorescence following gel electrophoresis (rhodamine) or estimation of molar mass by SDS-PAGE. This labelling procedure did not inhibit the actin capping capability (Fig. S6) and allowed production of CapZ capped actin filaments by polymerisation in the presence of CapZ. Quantum dots (incubation with 1−10 nM for 30 s - 1 min) were attached to the biotinylated CapZ after immobilization of the capped actin filaments on a HMM coated surface. Considering the effects of CapZ on actin filament length (Fig. S6), it is reasonable to presume that a majority of the filaments are capped with CapZ. The fact that <5% of the filaments bound quantum dots is most likely attributed to slow diffusion during a limited incubation period. This is in accordance with the low quantum dot binding along biotinylated actin filaments (see above). After quantum dot binding, an ATP-containing assay solution was added to observe motility (Movie S7). It can be seen in Fig. 5A–B (from overlapping 95% confidence intervals) that CapZ attachment was without consistent effect on HMM propelled actin filament velocity. This was tested and found to apply within the range of ionic strengths where a noticeable effect of gelsolin was seen in a recent study [49]. For practical reasons these results were obtained at rather low temperature (room temperature ~ 22°C). However, in a control experiment the effect of CapZ was also studied at higher temperature (~ 29°C, Fig. 5C). Neither in this case did the presence of CapZ significantly affect the sliding velocity provided that correction was performed for the fact that the filaments with CapZ were shorter. This is important because length per se, affects velocity (see [72] and Fig. S7). In the in vitro motility assay experiments with CapZ, the presence of the capping protein was either verified by the attachment of streptavidin coated quantum

| Sample                  | Velocity (mean ± SEM μm/s)^1/fraction of motile filaments With blocking actin | Without blocking actin |
|-------------------------|---------------------------------------------------------------------------------|------------------------|
| Actin-RhPh              | 2.02±0.09 (n = 20)/80% motile                                                  | 2.06±0.04 (33)/71% motile |
| Actin-APh               | 2.01±0.1 (24)/73% motile                                                       | 2.14±0.07 (23)/75% motile |
| Biotin-actin-RhPh       | 1.97±0.07 (96)/83% motile                                                      | 1.93±0.04 (37)/75% motile |
| Biotin-actin-APh        | 1.90±0.07 (51)/77% motile                                                      | 1.77±0.1 (26)/77% motile |
| Biotin-actin-APh + 1 quantum dot | 1.95±0.09 (17)/41% motile                                                      | 1.84±0.08 (52)/66% motile |

^1 A80 solution. No methylcellulose in assay solution. Motility assay performed at room temperature (21–23°C) and kept constant within ±0.5°C during each experiment. Number of filaments used for velocity measurements in parentheses. RhPh: rhodamin-phalloidin; APPh: AlexaFluor® 488 phalloidin.

doi:10.1371/journal.pone.0055931.t001

Figure 2. Motility quality for biotinylated actin filaments with 1−2 quantum dot cargoes attached along the filaments. A. Fraction of motile filaments in the absence (black) and presence (grey) of quantum dots. Error bars represent SEM. B. Sliding velocity for biotinylated F-actin without (black) and with (grey) quantum dots. Error bars represent 95% confidence intervals. Number of filaments given in parentheses.

doi:10.1371/journal.pone.0055931.g002
dots to biotinylated CapZ or by covalent rhodamine labelling. The fraction of motile filaments was not appreciably affected by the presence of CapZ and the fraction of motile filaments was higher than 50% for actin filaments that had quantum dots attached via CapZ.

The fact that CapZ did not affect the sliding velocity suggests that it should be useful to mediate attachment of quantum dots or magnetic particles [10] in fundamental studies of actomyosin function. Here, we exemplify this potential usefulness by demonstrating tracking with nanometer accuracy [47] of quantum dots attached to CapZ on HMM propelled actin filaments (Fig. S8). This allowed us to obtain accurate MgATP-velocity information at low MgATP concentration with frame rates as high as 5 s$^{-1}$ (Fig. 5D). Thus, the plot of velocity against [MgATP] is nearly linear in the range of 5–30 μM MgATP and extrapolates to zero as expected for a hyperbolic relationship between velocity and MgATP-concentration [67,73]. The non-zero velocity at [MgATP] = 0 μM reflects the approximately 5 nm uncertainty in each position estimate used for the velocity calculation. This is, however, considerably less than the uncertainty in the centroid tracking method [66]. As also shown in Fig. 5D, this centroid tracking method gives an apparent velocity of approximately 0.5 μm/s at 0 μM MgATP and also considerably higher velocities at micromolar MgATP concentrations than expected for a hyperbolic relationship.

Discussion

Methodological Issues

The fraction of motile filaments, the velocity of smoothly sliding filaments (CV<0.5), and the average velocity report different aspects of actomyosin function. The “smooth” velocity characterizes the optimal function under the condition studied. The average velocity, on the other hand, reports the velocity that would be most representative for the behaviour of an ensemble of moving filaments, e.g. in a nanodevice. Thus, in this case filaments were not selected based on the smoothness of sliding – all filaments were included even those that were stationary for all or a very small fraction of the measurement period. Importantly, the filaments moved for appreciably longer times and distances than generally used for velocity measurements (Fig. S3 and Fig. S4) and there was no substantial change in motility (velocity and fraction of motile filaments) over the periods (usually around 5 minutes) when measurements were made. This should be compared to less than 1 minute required for actomyosin driven concentration on a nanostructured surface [74]. Additionally, as the velocities did not change with time, measurements over short time periods for a large number of randomly selected filaments would be just as

![Figure 3. Motility quality vs. number of attached quantum dots on HMM propelled filaments. A. Fluorescence micrograph time series at 3 s intervals showing several motile and some non-motile and heavily quantum dot labelled actin filaments. All fluorescence in the micrographs is attributed to the quantum dots. The colour coded arrows point to some motile filaments/aggregates with 5 quantum dots (blue arrow; apparently single filament), >5 quantum dots and presumably 2 cross-linked filaments (orange arrow), small aggregate (white arrow), large aggregate (red arrow). B. The average fraction of motile filaments in 3 different experiments. Error bars: SEM (n=3 different flow cells and experimental occasions for different number of quantum dots; >3–11 quantum dot-labelled filaments per flow cell). The solid line (included for descriptive purpose) represents a single exponential function decaying with increased number of quantum dots to a plateau value. Optimal parameter values and 95% confidence interval (dotted lines) obtained by non-linear regression analysis. C. The mean sliding velocity ±95% confidence intervals in 3 (or 4; for 1–3 quantum dots) different experiments. The filled symbols and solid line represent the ten frames running average of the frame-to-frame velocities with lowest CV on the condition that CV<0.5. The open symbols and dashed line, on the other hand, represents average velocities calculated by dividing the integrated sliding distance with the tracking duration (11–14 s; shorter in the few cases when filaments moved out of the image). doi:10.1371/journal.pone.0055931.g003]
representative for the average velocity of the filament ensemble as measurements over more extended time periods.

Relation to Earlier Results

Covalent modification (by NHS-biotin) of up to 4 lysines per actin monomer affects neither the capability for actin polymerization nor the actomyosin motor function (see also Kumar et al. [32]). This brings new possibilities for extensive covalent modification of the lysines also for other purposes, e.g. attachment of antibodies at high densities along the actin filament for use in diagnostics applications [7,31,32]. The success of covalent biotinylation is also important for certain fundamental studies of actomyosin function [75,76] because the previously used alternative actin-phalloidin link [11,60] to couple biotin to actin has a limited half-life of <30 min [77]. The present motility assays with quantum dot attachment to covalently biotinylated actin filaments could, unlike those with biotin-phalloidin mediated quantum dot-attachment [11], be performed in the absence of viscosity enhancing methylcellulose in the assay solution at ionic strengths up to 80 mM (where actomyosin interactions are rather weak) without appreciable detachment of the actin filaments. This considerably improved motility suggests that effective actomyosin driven cargo-transportation is easier to achieve with side-attached cargoes than usually believed (cf. [7]). It is unclear whether the improved motility compared to the previous study [11] is due to geometrical differences between the two modes of biotinylation or to recent changes in commercial preparation of the streptavidin coated quantum dots (not revealed by Invitrogen for proprietary reasons). In spite of the improved motility compared to previous work [11], our results are, nevertheless, consistent with findings [39,51] that substantial cargo-loading of actin filaments with cargoes having diameters of tens of nanometers would give lower fraction of motile filaments. Importantly, however, we found only small effects on motility with small cargoes (of biotin-streptavidin size), even when the loading was quite extensive. The lower fraction of motile filaments with liposomes than with quantum dots supports the view (cf. [37]) that cargo-size is an important factor. Therefore, with large cargoes, unipolar actin bundles where the actin filaments are cross-linked via fascin [78], may be more effective [15,37] as HMM propelled shuttles than isolated actin filaments despite the increased complexity imposed by bundle production and need to maintain bundle integrity over time.

The effects of cargoes along actin filaments on actomyosin motility were generally of the all-or-none type. That is, if motility was inhibited it was usually completely switched off, at least temporarily, whereas only limited effects on sliding velocity were seen for motile filaments. This seems to be different from the inhibition of motility of microtubules propelled by conventional kinesin 1, where a substantial reduction in velocity was observed with increasing streptavidin loading of the filament [29,79]. These differences may be related to the fact that myosin II, in contrast to conventional kinesin motors, is non-processive. The processive motion of kinesin along microtubules would be temporarily blocked at a cargo “road-block” [29], but the kinesin motor could overcome the road-block without detaching [29], translating into a reduction of velocity for an ensemble of kinesins. In contrast, the detachment of a substantial fraction of active myosin II motors could lead to temporary or long-term switching off of motility and even detachment from the surface. The lack of cargo-effects on the sliding velocity might at first seem surprising, particularly in the presence of methylcellulose where drag forces might be of relevance. However, methylcellulose alters the macroscopic viscosity, but not the microscopic viscosity and therefore does not inhibit sliding filament velocity [72,80]. Also, a simple calculation suggests that the drag forces should be very small in any case. Thus, if a quantum dot is approximated by a sphere, the drag force \( F_{\text{drag}} \) is given by the relationship \( F_{\text{drag}} = 6\pi\eta rv \), where \( r \) is the quantum dot radius, \( v \) is the sliding velocity and \( \eta \) is the viscosity \(<150 \text{ cP for the type and concentration of methylcellulose used here} [72]. Now, inserting \( r<10 \text{ nm and } v<10 \mu\text{m/}\text{s} \) it follows that the viscous drag force on a quantum dot is less than 0.3 pN, i.e. considerably lower than the average force per myosin head of several pN [81]. In addition, at the HMM surface densities, ATP concentrations and velocities used here there are on the order of 10 myosin heads attached per \( \mu\text{m} \) of the filament at each given time [42]. Under these conditions the drag force would also be negligible for liposomes with radius five times higher than for a quantum dot.

More on Cargo Transportation with Side-attached Cargoes

In contrast to the lack of effects of covalent biotinylation, an increased fraction of stationary filaments and temporary stops in the sliding was observed upon increasing streptavidin, quantum
dot and liposome loading. Only small effects were seen with up to 50 streptavidins per mm of the actin filament. However, the effect was noticeably enhanced with increased cargo size and for a given number of cargoes. Thus the fraction of motile filaments progressively decreased from streptavidin over quantum dots to liposomes. This was the case in spite of a streptavidin layer on both the quantum dots and the liposomes. The inhibiting effects of the cargoes may be attributed to different forms of non-specific interactions with HMM and/or the prevention of myosin binding to actin. However, the HMM-quantum dot interactions seem to be weaker than interactions between quantum dots and the underlying TMCS-surface. Thus, increased non-specific surface binding of quantum dots was observed at low [MgATP] using nanometer tracking of quantum dots attached to CapZ (grey) or tracking the filament centroid (black) for the same filament (number of filaments in parentheses). Note appreciable overestimation of velocity at low [MgATP] by centroid tracking due to noise as most clearly indicated by the tracking of stationary filaments. The tracking of stationary quantum dots using the Gaussian fit (nanometer tracking) suggests a precision of <5 nm in each position estimate. This is based on the apparent speed of stationary quantum dots of 78 nm/s, a frame rate of 5 s⁻¹, the fact that the speed is a scalar quantity in the analysis and that each distance between frames, used for the velocity calculations, depends on two position estimates by Gaussian fits.

doi:10.1371/journal.pone.0055931.g005

Figure 5. Effect of CapZ binding to F-actin on HMM propelled actin filament velocity. A. Sliding velocities at different ionic strengths for F-actin with (grey) and without (black) CapZ/quantum dot complex (n=3 experimental occasions and different HMM preparations unless indicated in figure; >17 filaments analysed for each condition). Temperature: 22°C. Inset: two subsequent images (interval: 1.6 s) of HMM propelled RhPh-labelled F-actin (sliding to the right) with quantum dot attached to the trailing end via CapZ. B. Sliding velocities for F-actin capped with CapZ-rhodamine (dashed line, open symbols), CapZ/quantum dot complex (grey) and without CapZ (black) in one given experiment (number of filaments in parentheses). C. Effects of CapZ on sliding velocity at high temperature (28.6°C) in AMc130 assay solution. Average sliding velocities for F-actin in the absence of CapZ or in the presence of CapZ/quantum dot complex. Filament lengths of F-actin without CapZ limited to the mean length of CapZ capped actin filaments ±2 standard deviations (0–3 μm; see further Fig. S5, Fig. S7) to ensure comparability. Error bars in A–C: 95% CI. D. Velocity measurements (5 frames s⁻¹) at low [MgATP] using nanometer tracking of quantum dots attached to CapZ (grey) or tracking the filament centroid (black) for the same filament (number of filaments in parentheses). Note appreciable overestimation of velocity at low [MgATP] by centroid tracking due to noise as most clearly indicated by the tracking of stationary filaments. The tracking of stationary quantum dots using the Gaussian fit (nanometer tracking) suggests a precision of <5 nm in each position estimate. This is based on the apparent speed of stationary quantum dots of 78 nm/s, a frame rate of 5 s⁻¹, the fact that the speed is a scalar quantity in the analysis and that each distance between frames, used for the velocity calculations, depends on two position estimates by Gaussian fits.

doi:10.1371/journal.pone.0055931.g005

PLOS ONE | www.plosone.org 9 February 2013 | Volume 8 | Issue 2 | e55931
with the observation of several sequential rotations in the same direction of non-sliding actin filaments around actin-attached quantum dots (see above and Movie S4). Electrostatic interactions between the negative net charge of streptavidin at pH 7.4 and a positive electrostatic surface potential in the actin binding region of HMM [85,86] is unlikely to be of appreciable significance for the motility inhibition with few quantum dots because numerous streptavidin molecules were attached to actin filaments with only minimal effects on motility (cf. [29]). However, other types of non-specific interactions, e.g. hydrophobic, between the quantum dot itself and HMM, may be important. Here, it would be of interest to study how the chemical characteristics of the cargoes affects actomyosin function as studied recently for kinesin-microtubule cargo transportation [79].

Cargo-transportation in Relation to Mechanisms of Motion Generation and Actin Dynamics

A large fraction of filaments with 1–2 quantum dots and liposomes were observed to slide throughout the observation period (often >100 μm). Moreover, even rather large (>100 nm diameter) cargoes and/or several cargoes per filament were occasionally transported with minimal effects on velocity suggesting that rotation around the filament long axis during sliding is not of critical importance for chemomechanical energy transduction (cf. [45] and compare Fig. S1). The maintained high sliding velocity with heavy streptavidin loading of actin filaments is also consistent with this idea. This finding also argues against Brownian motor models [87] that explain actomyosin force generation by biased diffusion of myosin heads between binding sites with progressively lower energy on subsequent monomers along the actin filament. The similar size of streptavidin compared to the actin monomer and streptavidin labelling of almost 20% of the monomers would (assuming uniform distribution of streptavidins along the filament) limit the average number of diffusional steps of a myosin head along the filament to less than 2 before detachment at a streptavidin molecule. This is clearly less than proposed recently for a Brownian motor model [87]. If movement in such a model would occur along a given protofilament, the maximum distance before detachment with 2 steps would be about 10 nm, clearly less than the value of up to 30 nm at low load observed experimentally by Kitamura et al. [88].

For the use in studies of actomyosin function (e.g. [33]) it is important that attachment of e.g. fluorescent tags or other cargoes via plus end capping proteins does not affect actomyosin kinetics. Such effects may be expected for gelsolin mediated attachment if the kinetics is critically dependent on the actin filament structure since this structure is modified by interactions of gelsolin with subdomains 1 and 3 of the actin monomer [50,51,52,53]. Indeed, a study [49] using both Ca- and Mg-actin filaments nucleated in the presence of gelsolin seem to accord with effects of gelsolin on motility, whereas another study [33] did not detect such effects. Therefore, more studies are needed to resolve this issue. Further, the possibility to use fragments of gelsolin [50] or other capping proteins within the gelsolin family [89,90] may also be considered. Here we found no effects on motility of CapZ binding to the actin filament plus end. This is consistent with minimal structural changes along the actin filament upon CapZ binding, as expected because CapZ, unlike gelsolin, does not sever the filament. The usefulness of CapZ mediated attachment of quantum dots to actin filaments for future detailed functional studies of actomyosin is exemplified in Fig. 5D.

Cargo-transportation in Diagnostic Nanodevices

For use in diagnostic nanodevices, antibody coated actin filaments have recently [31,32] been proposed for capturing analyte molecules from solution for subsequent rapid motor driven concentration to a detector site on a nanostructured surface. Our finding that close to 20% of the actin monomers may be loaded with protein-sized cargoes without appreciable effect on motility is therefore essential. However, the use of antibody-coated filaments for capture of analytes would be of significance particularly at low analyte concentration when the need for signal amplification by actomyosin mediated concentration at a detector site is crucial. Under these conditions, very few (e.g. one or two) antibody-analyte complexes of sizes similar to quantum dots would be bound to each actin filament. We have demonstrated here that such limited cargo loading has quite small effects on motility quality.

Conclusions

We have demonstrated fast actomyosin based cargo transportation under a range of conditions using side-attached and end-attached model cargoes with different sizes similar to those of diagnostically relevant biomarkers and nanoparticles. The results, together with recent demonstration of long-term storage of actomyosin based nanodevices [91] guiding of actomyosin motility along nano-tracks [18] and covalent antibody attachment to actin filaments [31,32] support the usefulness of actomyosin for nanoseparation in medical diagnostics devices. The results with streptavidin loading also have potential implications for mechanistic models of actomyosin based motion generation and the effect may deserve further investigation. Finally, our results favour the use of CapZ, rather than gelsolin for mediating attachment of e.g. quantum dots or magnetic particles to the trailing end of actin filaments in various fundamental studies.

Supporting Information

Figure S1 Schematic illustration of streptavidin, quantum dots and liposome attachment to F-actin used in present work. A. Attachment of quantum dot and liposome along actin filament via biotin-streptavidin links. B. Attachment of quantum dot via a plus-end binding protein in the form of streptavidin labelled actin. A.

Figure S2 SDS-PAGE of CapZ, biotinylated CapZ and actin. A. Novex® 4–20% gradient tris-glycine acrylamide gel (Invitrogen) was run under reducing conditions and stained using Novex® colloidal blue staining kit (Invitrogen). Sample preparation, running conditions and staining procedure were performed according to manufacturer’s protocol. Lane 1– Purified CapZ expressed in Escherichia coli [1 μg, two subunits with 39 and 42 kDa apparent molecular weights], Lane 2– biotinylated CapZ (1 μg–6 biotins/CapZ molecule), Lane 3– rabbit skeletal actin (1 μg, 48 kDa apparent molecular weight). Lane 4– Protein standard SeeBlue® Plus 2 (Invitrogen). The apparent molecular weights in kDa are indicated on the gel. Lane 5– purity control for CapZ (10 μg). Lane 6– purity control for biotinylated CapZ (10 μg). Lane 7– purity control for rabbit skeletal actin (10 μg).

Figure S3 Matlab program output after tracking HMM propelled F-actin with long-distance transportation of quantum dot. This quantum dot was attached to biotinylated actin filament and the assay solution was a80. A. Sliding distance...
Actin Filaments as Molecular Shuttles

plotted against time during 28.2 s tracking period with a total distance of 120.4 μm. Average velocity, \( v_{avep} \), during this period calculated as the ratio \( v_{avep} = \frac{120.4 \times 28.2 \text{ μm}}{28.2 \text{ s}} \approx 4.27 \text{ μm/s} \). B. Frame-to-frame velocity plotted against frame number (at 0.2 s interval). C. Filament path in x-y-plane (250×250 pixels; 330 nm/pixel). D. The running average of “smoothest” sliding velocity (minimum coefficient of variation; CV) over ten frames plotted against the number of ten frame windows. E. The minimum ten-frame CV of the sliding velocity. Note, the mean velocity in D is updated for each reduction in CV in E to select the velocity of smoothest sliding. F. Minimum CV and corresponding mean velocity for 10-frame (CV-10; vmean-10) and 4-frame (CV-4; vmean-4) running averages from measurements illustrated in A–E. (TIF)

Figure S4 Velocity of actin filaments with cargoes does not change over a 10 min period. A. The velocity of smoothly sliding (CV<0.5) HMM-propelled actin filaments with 1 to 4 quantum dots in one experiment at different times after onset of recording. See inset for meaning of symbols. B. The average velocity (see Materials and Methods) of HMM-propelled actin filaments with 1 liposome in one experiment at different times after onset of recording. Each point in A and B refers to a given filament at the time point considered. Full lines and dashed lines represent regression line and 95% confidence intervals, respectively, both obtained in linear regression analysis. (TIF)

Figure S5 Actin filament with 4–5 quantum dots at each end, sliding downwards in the image. The unlabelled centre of the filament is surrounded by two straight yellow lines. The time interval between the two snapshots is 5.2 s. (TIF)

Figure S6 Effects of CapZ on actin filament length distribution. Monomeric actin was polymerized for 3 h in the absence and presence of CapZ/biotinylated CapZ and labelled with APh. Length measurements were done from images for HMM immobilized actin filaments in the absence of ATP. (TIF)

Figure S7 Sliding velocity vs. filament length for actin filaments without CapZ. The arrow represents the range of lengths (0–3 μm) covered by approximately 95% of the filaments with CapZ, measured when these filaments were bound to HMM in rigor (corresponding to mean ±2 standard deviation of the CapZ actin filament lengths). It is likely that the length was slightly reduced upon addition of MgATP due to filament fragmentation caused by motor induced shearing. Thus, the filaments without CapZ, used for velocity measurements, were only those with lengths in the range 0–3 μm in order to ensure reasonable comparability with the velocity of filaments with CapZ/quanum dots complex. The length of the latter filaments was generally not measured for practical reasons. Temperature: 28.6°C. HMM incubation concentration, 120 μg/ml. AMc130 assay solution. Filament lengths measured from intensity data as described by Sundberg et al. [42] to account for errors due to filament motion during exposure time and diffraction limitation for short filaments. (TIF)

Figure S8 Tracking of quantum dots with nm accuracy. Intensity profiles (bottom) of stationary quantum dot (bright spots at top left; 40×40 μm²) were fitted by two-dimensional Gaussian function for each image frame (frame rate 5 s⁻¹). Brownian motion, tracking errors etc. (from tracking in the x-y plane for 1.8 s) gave a variation in position of less than 10 nm suggesting that tracking was possible with <10 nm accuracy. (TIF)

Movie S1 HMM-propelled actin filaments coated with streptavidin attached to the filaments via biotinylated actin. Covalently biotinylated actin filaments (5 nM; monomer concentration; 4 biotins/actin) were immobilized on HMM in the flow cell and then incubated with 1 nM TRITC-labelled streptavidin for 1 min. The actin filaments were also labelled with Alexa-488 phalloidin. The movie first illustrates the TRITC-labelled streptavidin using a TRITC filter set followed by observation of the entire filaments using a FITC filter set (approximately 7–13 s into movie) and finally, the TRITC-labelled streptavidin, again. Note that two filaments self-organize into spools. Main Fig. 1A extracted from movie. Frame rate: 5 s⁻¹ (real time) and image size: 85×85 μm². (MOV)

Movie S2 HMM-propelled actin filaments coated with streptavidin attached to the filaments via biotinylated actin. Actin filaments (5 nM; monomer concentration; 4 biotins/actin) were immobilized on HMM in the flow cell and then incubated with 20 nM TRITC-labelled streptavidin for 1 min. The concentration of free biotin to block unoccupied biotin-sites of streptavidin was 40 μM. The actin filaments were also labelled with Alexa-488 phalloidin. The movie first illustrates the TRITC-labelled streptavidin using a TRITC filter set followed by observation of the entire filaments using a FITC filter set at the end. Main Fig. 1B extracted from movie. Frame rate: 5 s⁻¹ (real time) and image size: 85×85 μm². (AVI)

Movie S3 HMM-propelled actin filaments with streptavidin coated quantum dots attached to the filaments via biotinylated actin. The actin filaments were also labelled with Alexa-488 phalloidin. The movie first illustrates a few frames with the FITC filter set to observe the entire filaments whereas the remaining frames were obtained using the TRITC filter set to observe the quantum dots with emission maximum at 605 nm. Filaments and quantum dots pseudocolored to indicate their different emission maxima. Note, 1. that only a small fraction of the filaments are labelled with quantum dots and 2. that there is a substantial number of non-specifically bound quantum dots, falsely indicating a large number of stationary actin filaments with quantum dots. From series of experiments in Fig. 2 (a80 solution). Frame rate: 5 s⁻¹ (real time) and image size: 85×85 μm². (MOV)

Movie S4 HMM-propelled actin filaments with streptavidin coated quantum dots attached to the filaments via biotinylated actin. The filaments were dually labelled and observed using a filter that simultaneously allows observation of Alexa-488 and quantum dots (emission maximum at 605 nm). Note, large number of quantum dots (>5) attached to, presumably, two cross-linked filaments at top left (no free biotin in assay solution). Note further that one filament with two quantum dots (one at very front) that moves to the right, suddenly stops and begins to rotate counter-clockwise for five consecutive turns. This indicates unconstrained rotation around one of the quantum dots as an axis and continuous driving of this rotation by appropriately located HMM molecules. From series of experiments in Fig.3 (a80 solution). Frame rate: 5 s⁻¹ (real time). Image size: 46×33 μm². (MOV)
Movie S5 HMM-propelled actin filaments with calcein loaded liposomes attached to the filaments via streptavidin and biotinylated actin. In order to observe the liposomes in the movie was recorded using the FITC filter set. Note, that not all stationary liposomes represent stationary filaments due to non-specific binding of liposomes to the surface. Note further, 1. single “small” liposomes are rather photobleached, 2. one large liposome appears to “roll” over the surface (mid, top). From series of experiments in Fig.4 (AVI solution). Frame rate: 5 s⁻¹ (real time) and image size: 85×85 μm².

(MOV)

Movie S6 HMM-propelled actin filaments with calcein loaded liposomes attached to the filaments via streptavidin and biotinylated actin. The actin filaments were also labelled with tetramethylrhodamineisothiocyanate (TRITC)-phalloidin. Initially the recording was made using a FITC filter allowing observation of the liposomes. The filter set was then, approximately in the middle of the movie, switched to a TRITC filter set to allow observation of the actin filaments. Note, apparent rolling of liposome over surface. Frame rate: 5 s⁻¹ (real time) and image size: 20×25 μm².

(MOV)

Movie S7 HMM-propelled actin filaments with quantum dots attached to the actin filaments via biotinylated CapZ at the plus-end. The actin filaments were also labelled with Alexa-488 phalloidin. The movie first illustrates a few frames recorded with the TRITC filter set to observe quantum dots. For a short sequence in the movie the filter set is changed to FITC to observe the entire filaments whereas the remaining frames were obtained using the TRITC filter set to observe the quantum dots again. Note, that only a small fraction of the filaments are labelled with quantum dots and that a large fraction of the stationary quantum dots were non-specifically attached to the surface. HMM incubation concentration 120 μg/ml. From series of experiments in Fig. 5 (A60 solution). Frame rate: 5 s⁻¹ (real time) and image size: 85×85 μm².

(AVI)

Abbreviations S1 List of abbreviations. (DOC)

Acknowledgments
The authors wish to thank Dr. N. N. Vakhareva for her contributions to the experimental work, Professor T. Ohnata, Chiba University, Yayoi-cho, Inage-ku, Chiba-shi, Japan and Professor Y. Maeda, RIKEN Harima Institute, Kouto, Sayo-cho, Sayo-gun, Hyogo, JAPAN, for providing the CapZ expression plasmid. Finally, we wish to thank Dr. R. Martinez-Neira for contributions to preliminary experiments.

Author Contributions
Conceived and designed the experiments: MP ML AM AK. Performed the experiments: MP MG CT. Analyzed the data: MP AM. Wrote the paper: MP MG CT ML AM AK.

References
1. Vale RD (2003) The molecular motor toolbox for intracellular transport. Cell 112: 467–480.
2. Howard J (2001) Mechanics of motor proteins and the cytoskeleton. Sunderland, MA: Sinauer Associates Inc.
3. Agarwal A, Hess H (2010) Biomolecular motors at the intersection of nanotechnology and polymer science. Progress in Polymer Science 35: 252–277.
4. Bakewell DJG, Nicolau DV (2007) Protein linear molecular motor-powered nanodevices. Australian Journal of Chemistry 60: 314–332.
5. Goel A, Vogel V (2008) Harnessing biological motors to engineer systems for nanoscale transport and assembly. Nature Nanotechnology 3: 465–475.
6. van den Heuvel MGL, Dekker C (2007) Motor proteins at work for nanotechnology. Science 317: 333–336.
7. Korten T, Månsson A, Diez S (2010) Towards the Application of Cytoskeletal Motor Proteins in Molecular Detection and Diagnostic Devices. Current Opinion in Biotechnology 21: 477–480.
8. Brummer C, Wohlers C, Vogel V (2007) Cargo pick-up from engineered loading stations by kinesin-driven molecular shuttles. Lab on a Chip 7: 1263–1271.
9. Hatton BM, Platt M, Hancock WO, Williams ME (2007) Directing transport of CoFe2O4-functionalized microtubules with magnetic fields. Small 3: 126–131.
10. Marston SB, Holohan SJF (2005) Force-velocity relationship of single actin filament interacting with immobilized myosin measured by electromagnetic techniques. IEEE Proceedings of Nanobiotechnology 152: 113–120.
11. Månsson A, Sundberg M, Balaz K, Bank R, Nicholls IA, et al. (2004) In vitro sliding of actin filaments labelled with single quantum dots. Biochem Biophys Res Commun 314: 329–334.
12. Bachand GD, Rivera SB, Beal AK, Gaudioso J, Liu J, et al. (2004) Assembly and transport of nanocrystal CdSe quantum dot composites using microtubules and kinesin motor proteins. Nano Letters 4: 817–821.
13. Bachand GD, Rivera SB, Carroll-Portillo A, Hess H, Bachand M (2006) Active capture and transport of virus particles using a biomolecular motor-driven, nanoscale antibody sandwich assay. Small 2: 301–305.
14. Ramachandran S, Ernst KH, Bachand GD, Vogel V, Hess H (2006) Selective loading of kinesin-powered molecular shuttles with protein cargo and its application to biosensing. Small 2: 330–334.
15. Takeda SI, Rhee KM, Asano S, Day BS, Hino M, et al. (2010) Utilization of myosin and actin filaments for the transport of molecular cargo. Small 6: 452–457.
16. Taira S, Du YZ, Hiratsuka Y, Komishi K, Kubo T, et al. (2006) Selective detection and transport of fully matched DNA by DNA-loaded microtubule and kinesin motor protein. Biotechnology and Bioengineering 55: 533–538.
17. Taira S, Du YZ, Hiratsuka Y, Uyeda TQ, Yumoto N, et al. (2008) Loading and unloading of molecular cargo by DNA-conjugated microtubule. Biotechnology and Bioengineering 99: 734–739.
18. Sundberg M, Bank R, Albet-Torres N, Kennefors A, Pesson F, et al. (2006) Actin filament guidance on a chip: toward high-throughput assays and lab-on-a-chip applications. Langmuir 22: 7286–7295.
19. Månsson A, Sundberg M, Bank R, Balaz M, Nicholls IA, et al. (2005) Actin-based molecular motors for cargo transportation in nanotechnology - potentials and challenges. IEEE trans Adv Pack 28: 547–555.
20. Hess H, Clemmens J, Qin D, Howard J, Vogel V (2001) Light-controlled molecular shuttles made from motor proteins carrying cargo on engineered surfaces. Nano Letters 1: 235–239.
21. Diez S, Reuther C, Dinu C, Seidel R, Mertig G, et al. (2003) Stretching and transporting DNA molecules using motor proteins. Nano Letters 3: 1251–1254.
22. Dinu CZ, Opata J, Pompe W, Howard J, Mertig G, et al. (2006) Parallel manipulation of bifunctional DNA molecules on structured surfaces using kinesin-driven molecular shuttles. Small 2: 1098–1099.
23. Jia LL, Moorjani SG, Jackson TN, Hancock WO (2004) Microscale transport and sorting by kinesin molecular motors. Biomedical Microdevices 6: 67–74.
24. Huang YM, Uppalapati M, Hancock WO, Jackson TN (2007) Microtube transport, concentration and alignment in enclosed microfluidic channels. Biomedical Microdevices 9: 175–184.
25. Kim T, Cheng LJ, Kao MT, Haselbrink EF, Guo L, et al. (2009) Bimolecular motor-driven molecular sorter. Lab on a Chip 9: 1292–1293.
26. Hiratsuka Y, Tada T, Osaw K, Kanayama T, Uyeda TQ (2001) Controlling the direction of kinesin-driven microtubule movements along microlithographic tracks. Biophys J 81: 1555–1561.
27. Clemmens J, Hess H, Doot R, Matzke CM, Bachand GD, et al. (2004) Motor-protein “roundabouts”: Microtubules moving on kinesin-coated tracks through engineered networks. Lab on a Chip 4: 83–86.
28. Fischer T, Agarwal A, Hess H (2009) A smart dust biosensor powered by kinesin motors. Nat Nanotechnol 4: 162–166.
29. Korten T, Diez S (2008) Setting up roadblocks for kinesin-1: mechanism for the selective speed control of cargo carrying microtubules. Lab on a Chip 8: 1441–1447.
30. Rios L, Bachand GD (2009) Multiplex transport and detection of cytokines using kinesin-driven molecular shuttles. Lab on a Chip 9: 1005–1010.
31. Kumar S, Albet-Torres N, Paderi F, ten Siethoff L, Persson M, et al. (2011) An alternative to microfluidics: Antibody-surface complexed transport by actomyosin motors. Abstract of 2nd International Conference on Bio-sensing Technology, Amsterdam, October 10–20.
32. Kumar S, ten Siethoff L, Persson M, Lard M, de Kreunen G, et al. (2012) Antibodies covalently immobilized on actin filaments for fast myosin driven analyte transport. PLoS One 7: e62982.
33. Suzuki N, Miyata H, Ishiwata S, Kinosita K Jr (1996) Preparation of bead-tailed actin filaments for in vitro motility assay. Biophys J 71: 401–406.
46. Wells AL, Lin AW, Chen LQ, Safer D, Cain SM, et al. (1999) Myosin VI is an
42. Sundberg M, Balaz M, Bunk R, Rosengren-Holmberg JP, Montelius L, et al.
41. Iwabuchi S, Takahashi T, Hatori K (2012) Transport of actin-decorated
37. Takatsuki H, Tanaka H, Rice KM, Kolli MB, Nalabotu SK, et al. (2011)
36. Soto CM, Martin BD, Sapsford KE, Blum AS, Ratna BR (2008) Toward single
35. Chen Y, Guzik S, Sumner JP, Moreland J, Koretsky AP (2011) Magnetic
34. Kaur H, Kumar S, Sukkar D, Kaur I, Singh K, et al. (2010) Transportation of
33. Chen Y, Guzik S, Sumner JP, Moreland J, Kowrska AP (2011) Magnetic
32. Soto CM, Martin BD, Bunk R, Rosengren-Holmberg JP, Montelius L, et al. (2010)
31. Takatsuki H, Tanaka H, Rice KM, Kolli MB, Nalabotu SK, et al. (2011)
30. Wells AL, Lin AW, Chen LQ, Safer D, Cain SM, et al. (1999) Myosin VI is an
29. Chen Y, Guzik S, Sumner JP, Moreland J, Koretsky AP (2011) Magnetic
28. Soto CM, Martin BD, Bunk R, Rosengren-Holmberg JP, Montelius L, et al. (2010)
27. Takatsuki H, Tanaka H, Rice KM, Kolli MB, Nalabotu SK, et al. (2011)
26. Soto CM, Martin BD, Bunk R, Rosengren-Holmberg JP, Montelius L, et al. (2010)
25. Takatsuki H, Tanaka H, Rice KM, Kolli MB, Nalabotu SK, et al. (2011)
24. Takatsuki H, Tanaka H, Rice KM, Kolli MB, Nalabotu SK, et al. (2011)
23. Takatsuki H, Tanaka H, Rice KM, Kolli MB, Nalabotu SK, et al. (2011)
22. Soto CM, Martin BD, Bunk R, Rosengren-Holmberg JP, Montelius L, et al. (2010)
21. Takatsuki H, Tanaka H, Rice KM, Kolli MB, Nalabotu SK, et al. (2011)
20. Takatsuki H, Tanaka H, Rice KM, Kolli MB, Nalabotu SK, et al. (2011)
19. Takatsuki H, Tanaka H, Rice KM, Kolli MB, Nalabotu SK, et al. (2011)
18. Takatsuki H, Tanaka H, Rice KM, Kolli MB, Nalabotu SK, et al. (2011)
17. Takatsuki H, Tanaka H, Rice KM, Kolli MB, Nalabotu SK, et al. (2011)
16. Takatsuki H, Tanaka H, Rice KM, Kolli MB, Nalabotu SK, et al. (2011)
15. Takatsuki H, Tanaka H, Rice KM, Kolli MB, Nalabotu SK, et al. (2011)
14. Takatsuki H, Tanaka H, Rice KM, Kolli MB, Nalabotu SK, et al. (2011)
13. Takatsuki H, Tanaka H, Rice KM, Kolli MB, Nalabotu SK, et al. (2011)
12. Takatsuki H, Tanaka H, Rice KM, Kolli MB, Nalabotu SK, et al. (2011)
11. Takatsuki H, Tanaka H, Rice KM, Kolli MB, Nalabotu SK, et al. (2011)
10. Takatsuki H, Tanaka H, Rice KM, Kolli MB, Nalabotu SK, et al. (2011)
9. Takatsuki H, Tanaka H, Rice KM, Kolli MB, Nalabotu SK, et al. (2011)
8. Takatsuki H, Tanaka H, Rice KM, Kolli MB, Nalabotu SK, et al. (2011)
7. Takatsuki H, Tanaka H, Rice KM, Kolli MB, Nalabotu SK, et al. (2011)
6. Takatsuki H, Tanaka H, Rice KM, Kolli MB, Nalabotu SK, et al. (2011)
5. Takatsuki H, Tanaka H, Rice KM, Kolli MB, Nalabotu SK, et al. (2011)
4. Takatsuki H, Tanaka H, Rice KM, Kolli MB, Nalabotu SK, et al. (2011)
3. Takatsuki H, Tanaka H, Rice KM, Kolli MB, Nalabotu SK, et al. (2011)
2. Takatsuki H, Tanaka H, Rice KM, Kolli MB, Nalabotu SK, et al. (2011)
1. Takatsuki H, Tanaka H, Rice KM, Kolli MB, Nalabotu SK, et al. (2011)